Keep the questions. Take your time.
Fact check
Ask what was tested, in whom, and whether the result answers your question. Keep an animal finding separate from a human result.
Under the BPC-157 name, the FDA found several chemical versions being sold. The FDA’s work as a US agency includes medicine reviews. These are differences in the actual substance, beyond a choice of injection or pill.
Ask for the exact ingredient name and who made it. Keep that answer beside the study being used to support the offer.
In the FDA review available on September 28, 2026, five human studies involved about eighty people receiving BPC-157.
Only two studies had a group for comparison. Both were published as brief summaries for meetings, without a full report of how the study was done and what it found.
In those studies, people given BPC-157 were compared with people given a dummy treatment containing no BPC-157.
Healing findings
in rats
Does it help
this concern?
Without a comparison group, the knee-pain report cannot tell whether BPC-157 explains the improvement.
At the September 28, 2026 check, the registered hamstring-injury trial was recruiting and had no results.
A trial record describes a study’s plans and progress. It is not itself a finding that the treatment works.
No. The groups seeking FDA permission for pharmacies to use BPC-157 later withdrew their requests. The withdrawals appear in an FDA table; the page dates its current information to April 22, 2026.
Taking back those requests did not give BPC-157 FDA approval.
The FDA page gives no date for when the requests were taken back.
No. Federal ingredient rules barred a regular pharmacy from making BPC-157 with raw ingredients at the September 26, 2026 check.
BPC-157 met none of the required conditions. It had no official written standard for what the ingredient must contain and how its quality is tested. No approved drug used BPC-157 as an ingredient. It was also absent from the FDA list permitting raw ingredients for use by these pharmacies.
A prescription alone does not change those ingredient rules.
An FDA committee met in July 2026 to advise the agency about ingredients for pharmacy use. FDA staff had proposed keeping BPC-157 off the permitted list.
A draft HHS policy dated October 30, 2026 says the advisers voted in favor of adding BPC-157. FDA minutes remain unpublished. That missing record does not tell us how the committee voted.
The committee gives advice. Changing the permitted ingredients requires a formal FDA rule change, with public comments invited as part of the process.